MARKET

PAHC

PAHC

Phibro Animal
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.73
+0.03
+0.16%
Opening 13:53 05/18 EDT
OPEN
18.53
PREV CLOSE
18.70
HIGH
18.85
LOW
18.48
VOLUME
32.44K
TURNOVER
211.90K
52 WEEK HIGH
31.00
52 WEEK LOW
17.28
MARKET CAP
758.63M
P/E (TTM)
12.90
1D
5D
1M
3M
1Y
5Y
Does This Valuation Of Phibro Animal Health Corporation (NASDAQ:PAHC) Imply Investors Are Overpaying?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Phibro Animal Health...
Simply Wall St. · 05/10 10:45
Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up
In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.
Zacks · 05/06 14:34
Phibro Animal Reports Mixed Q3 Earnings, Lifts FY22 Sales Outlook
Benzinga · 05/05 12:31
Phibro Animal Health (PAHC) Q3 Earnings Miss Estimates
Phibro (PAHC) delivered earnings and revenue surprises of -8.33% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 23:45
Phibro Animal Non-GAAP EPS of $0.33 misses by $0.02, revenue of $239.6M beats by $9.07M
Phibro Animal press release (NASDAQ:PAHC): Q3 Non-GAAP EPS of $0.33 misses by $0.02. Revenue of $239.6M (+13.0% Y/Y) beats by $9.07M. Fiscal year 2022 guidance:  Net sales of approximately $930
Seekingalpha · 05/04 21:15
Phibro Animal Health Q3 EPS $0.33 Misses $0.35 Estimate, Sales $239.60M Beat $226.26M Estimate
Phibro Animal Health (NASDAQ:PAHC) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.35 by 5.71 percent. This is a 2.94 percent decrease over earnings of $0.34 per share
Benzinga · 05/04 21:02
-- Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q3 Revenue $239.6M, vs. Street Est of $230.5M
MT Newswires · 05/04 16:42
Phibro Animal Health Corporation declares $0.12 dividend
Phibro Animal Health Corporation (NASDAQ:PAHC) declares $0.12/share quarterly dividend, in line with previous. Forward yield 2.67% Payable June 22; for shareholders of record June 1; ex-div May 31.
Seekingalpha · 05/02 20:23
More
No Data
Learn about the latest financial forecast of PAHC. Analyze the recent business situations of Phibro Animal through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
66.67%Hold
33.33%Under-perform
0.00%Sell
Analyst Price Target
The average PAHC stock price target is 21.00 with a high estimate of 23.00 and a low estimate of 18.00.
High23.00
Average21.00
Low18.00
Current 18.67
EPS
Actual
Estimate
0.100.190.280.38
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 228
Institutional Holdings: 27.78M
% Owned: 68.58%
Shares Outstanding: 40.50M
TypeInstitutionsShares
Increased
42
685.35K
New
17
273.80K
Decreased
58
775.33K
Sold Out
14
157.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.80%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jack Bendheim
Chief Financial Officer
Damian Finio
Corporate Executive/Director
Jonathan Bendheim
Corporate Executive
Rob Aukerman
Chief Operating Officer
Larry Miller
Executive Vice President/Director
Daniel Bendheim
Senior Vice President/General Counsel/Secretary
Thomas Dagger
Senior Vice President/Director of Human Resources
Lisa Escudero
Vice President - Finance/Treasurer
Anthony Andolino
Independent Director
Gerald Carlson
Independent Director
E. Corcoran
Independent Director
Sam Gejdenson
Independent Director
Mary Malanoski
Independent Director
Carol Wrenn
No Data
No Data
About PAHC
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The Company sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.

Webull offers kinds of Phibro Animal Health Corp stock information, including NASDAQ:PAHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PAHC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PAHC stock methods without spending real money on the virtual paper trading platform.